Comparative Pharmacology
Head-to-head clinical analysis: HALOPERIDOL LACTATE versus THIOTHIXENE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HALOPERIDOL LACTATE versus THIOTHIXENE.
HALOPERIDOL LACTATE vs THIOTHIXENE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Haloperidol lactate is a typical antipsychotic that exerts its effects primarily by blocking dopamine D2 receptors in the brain, particularly in the mesolimbic and mesocortical pathways. It also has antagonistic activity at alpha-1 adrenergic receptors and limited affinity for serotonin receptors.
Thiothixene is a typical antipsychotic that blocks postsynaptic dopamine D1 and D2 receptors in the brain. It also has alpha-adrenergic and histamine H1 blocking activity, with minimal anticholinergic effects.
2-5 mg intramuscularly or intravenously every 4-8 hours for acute agitation. Maximum 20 mg/day.
Initial: 2 mg orally three times daily; maintenance: 5-30 mg/day orally in divided doses; maximum: 60 mg/day. IM: 4 mg 2-4 times daily; maximum 30 mg/day.
None Documented
None Documented
Clinical Note
moderateThiothixene + Deferasirox
"The serum concentration of Deferasirox can be increased when it is combined with Thiothixene."
Clinical Note
moderateThiothixene + Fluticasone propionate
"The risk or severity of adverse effects can be increased when Thiothixene is combined with Fluticasone propionate."
Clinical Note
moderateThiothixene + Tenofovir disoproxil
"The metabolism of Tenofovir disoproxil can be decreased when combined with Thiothixene."
Clinical Note
moderate14–26 hours (terminal elimination half-life); may be prolonged in hepatic impairment or with repeated dosing due to accumulation.
Terminal half-life: 10-20 hours (mean ~14 h). Clinical context: Steady-state achieved in ~2-3 days; allows once-daily dosing for maintenance.
Renal (approximately 40% as metabolites, <1% as unchanged drug); fecal (approximately 15%); remainder metabolized with unknown fate.
Primarily renal: 65-70% as metabolites, <1% unchanged. Fecal: 15-20% via biliary elimination.
Category A/B
Category C
Typical Antipsychotic
Typical Antipsychotic
Thiothixene + Methylphenidate
"The risk or severity of adverse effects can be increased when Thiothixene is combined with Methylphenidate."